Pancreatic Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Pancreatic Cancer - Pipeline Review, H1 2016

Pancreatic Cancer - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Pancreatic Cancer - Pipeline Review, H1 2016
Published Jun 28, 2016
1827 pages — Published Jun 28, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Pancreatic Cancer - Pipeline Review, H1 2016, provides an overview of the Pancreatic Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Pancreatic Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pancreatic Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Pancreatic Cancer
- The report reviews pipeline therapeutics for Pancreatic Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Pancreatic Cancer therapeutics and enlists all their major and minor projects
- The report assesses Pancreatic Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Pancreatic Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Pancreatic Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pancreatic Cancer pipeline depth and focus of Indication th

  
Source:
Document ID
GMDHC7953IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents269
  List of Tables619
  List of Figures701
Introduction711
  Global Markets Direct Report Coverage711
Pancreatic Cancer Overview721
Therapeutics Development732
  Pipeline Products for Pancreatic Cancer Overview731
  Pipeline Products for Pancreatic Cancer Comparative Analysis741
Pancreatic Cancer Therapeutics under Development by Companies7526
Pancreatic Cancer Therapeutics under Investigation by Universities/Institutes1013
Pancreatic Cancer Pipeline Products Glance1044
  Late Stage Products1041
  Clinical Stage Products1051
  Early Stage Products1061
  Unknown Stage Products1071
Pancreatic Cancer Products under Development by Companies10833
Pancreatic Cancer Products under Investigation by Universities/Institutes1414
Pancreatic Cancer Companies Involved in Therapeutics Development145282
  3-V Biosciences, Inc.1451
  4SC AG1461
  AB Science SA1471
  AbbVie Inc.1481
  AbGenomics International, Inc.1491
  Ability Pharmaceuticals, S.L.1501
  Acetylon Pharmaceuticals, Inc.1511
  ACF Pharmaceuticals, LLC1521
  Adamed Sp. z o.o.1531
  Adamis Pharmaceuticals Corporation1541
  Aduro BioTech, Inc.1551
  Advantagene, Inc.1561
  Advaxis, Inc.1571
  Agenus, Inc.1581
  AGV Discovery, SAS1591
  AIMM Therapeutics B.V.1601
  Alchemia Limited1611
  Alethia Biotherapeutics Inc.1621
  Allinky Biopharma1631
  Almac Discovery Limited1641
  Altor BioScience Corporation1651
  Ambrx, Inc.1661
  American Gene Technologies International Inc.1671
  Amgen Inc.1681
  Anavex Life Sciences Corp.1691
  Andarix Pharmaceuticals, Inc.1701
  ANP Technologies, Inc.1711
  AntiCancer, Inc.1721
  APEIRON Biologics AG1731
  Aphios Corporation1741
  APIM Therapeutics AS1751
  Apogenix GmbH1761
  Aposense Ltd.1771
  ArQule, Inc.1781
  Array BioPharma Inc.1791
  Astellas Pharma Inc.1801
  AstraZeneca Plc1811
  ATLAB Pharma SAS1821
  Aurigene Discovery Technologies Limited1831
  AVEO Pharmaceuticals, Inc.1841
  Axcentua Pharmaceuticals AB1851
  Azaya Therapeutics, Inc.1861
  Basilea Pharmaceutica AG1871
  Bavarian Nordic A/S1881
  Bayer AG1891
  Bellicum Pharmaceuticals, Inc.1901
  Berg LLC1911
  BerGenBio AS1921
  Betta Pharmaceuticals Co. Ltd.1931
  Bexion Pharmaceuticals, LLC.1941
  Biomar Microbial Technologies1951
  Biomunex Pharmaceuticals1961
  Bioncotech Therapeutics S.L.1971
  Bionomics Limited1981
  BioNTech AG1991
  BiOrion Technologies B.V.2001
  Biotest AG2011
  Biouniversa s.r.l.2021
  Boehringer Ingelheim GmbH2031
  Boston Biomedical, Inc.2041
  Bristol-Myers Squibb Company2051
  Cadila Pharmaceuticals Limited2061
  Calithera Biosciences, Inc.2071
  Cantargia AB2081
  Cascadian Therapeutics Inc2091
  Cavion LLC2101
  Celgene Corporation2111
  Cellceutix Corporation2121
  Cellectis S.A.2131
  Cellular Biomedicine Group, Inc.2141
  Celprogen, Inc.2151
  Celsion Corporation2161
  Centrose LLC2171
  Ceronco Biosciences2181
  ChemoCentryx, Inc.2191
  Chiome Bioscience, Inc.2201
  Clovis Oncology, Inc.2211
  Coare Biotechnology, Inc.2221
  Concordia Healthcare Corp.2231
  Confluence Life Sciences, Inc.2241
  Cornerstone Pharmaceuticals, Inc.2251
  Critical Outcome Technologies Inc.2261
  CritiTech, Inc.2271
  CrystalGenomics, Inc.2281
  CTI BioPharma Corp.2291
  Cyclacel Pharmaceuticals, Inc.2301
  CytomX Therapeutics, Inc.2311
  CytRx Corporation2321
  CyTuVax B.V.2331
  Daewoong Pharmaceutical Co., Ltd.2341
  DEKK-TEC, Inc.2351
  Dicerna Pharmaceuticals, Inc.2361
  Diffusion Pharmaceuticals Inc.2371
  Eisai Co., Ltd.2381
  Eleison Pharmaceuticals LLC2391
  Eli Lilly and Company2401
  Endor Nanotechnologies SL2411
  Ensol Biosciences Inc.2421
  Erytech Pharma SA2431
  Esperance Pharmaceuticals, Inc.2441
  Etubics Corporation2451
  Exelixis, Inc.2461
  F. Hoffmann-La Roche Ltd.2471
  FibroGen, Inc.2481
  Five Prime Therapeutics, Inc.2491
  Forty Seven Inc.2501
  Fountain Biopharma Inc.2511
  Fujifilm Corporation2521
  Fusion Antibodies Limited2531
  GamaMabs Pharma S.A.2541
  Ganymed Pharmaceuticals AG2551
  Geistlich Pharma AG2561
  Genelux Corporation2571
  Genentech, Inc.2581
  Genisphere Inc.2591
  Genmab A/S2601
  Gilead Sciences, Inc.2611
  GlaxoSmithKline Plc2621
  Globeimmune, Inc.2631
  GlycoMimetics, Inc.2641
  Golden Biotechnology Corp.2651
  GW Pharmaceuticals Plc2661
  Halozyme Therapeutics, Inc.2671
  HEC Pharm Co., Ltd.2681
  Helix BioPharma Corp.2691
  iCeutica, Inc.2701
  Ignyta, Inc.2711
  Immodulon Therapeutics Ltd.2721
  Immune Pharmaceuticals Inc.2731
  Immune System Key Ltd.2741
  Immunomedics, Inc.2751
  Immunotope, Inc.2761
  Immunovo BV2771
  Immupharma Plc2781
  Incuron, LLC2791
  Incyte Corporation2801
  Inflection Biosciences Limited2811
  Innopharmax Inc.2821
  Inovio Pharmaceuticals, Inc.2831
  Intica Biomedical, Inc.2841
  Inventiva2851
  Io Therapeutics, Inc.2861
  Ipsen S.A.2871
  Jasco Pharmaceuticals, LLC.2881
  Jiangsu Hengrui Medicine Co., Ltd.2891
  Johnson &Johnson2901
  Juno Therapeutics Inc.2911
  Kadmon Corporation, LLC2921
  Kancera AB2931
  Karcinolys SAS2941
  Karyopharm Therapeutics, Inc.2951
  Keystone Nano, Inc.2961
  Komipharm International Co., Ltd.2971
  Kura Oncology, Inc.2981
  Kyowa Hakko Kirin Co., Ltd.2991
  Lymphocyte Activation Technologies, S.A.3001
  MabVax Therapeutics Holdings, Inc.3011
  MacroGenics, Inc.3021
  Mateon Therapeutics Inc3031
  MaxiVAX SA3041
  Meabco A/S3051
  Mebiopharm Co., Ltd.3061
  MediaPharma s.r.l.3071
  Medicenna Therapeutics, Inc.3081
  MedImmune, LLC3091
  Medisyn Technologies, Inc.3101
  Medivation, Inc.3111
  Merck &Co., Inc.3121
  Merck KGaA3131
  Merrimack Pharmaceuticals, Inc.3141
  Merus B.V.3151
  Midatech Pharma Plc3161
  MolMed S.p.A.3171
  Momenta Pharmaceuticals, Inc.3181
  Monopar Therapeutics LLC3191
  Morphotek, Inc.3201
  Multimmune GmbH3211
  Mundipharma International Ltd3221
  NanoCarrier Co., Ltd.3231
  NantKwest, Inc.3241
  Nascent Biotech, Inc.3251
  Natco Pharma Limited3261
  NatureWise Biotech &Medicals Corporation3271
  Nerviano Medical Sciences S.r.l.3281
  NewLink Genetics Corporation3291
  NormOxys, Inc.3301
  Northwest Biotherapeutics, Inc.3311
  Novartis AG3321
  NuCana BioMed Limited3331
  Omeros Corporation3341
  Omnitura Therapeutics Inc.3351
  Oncodesign SA3361
  Oncodrone BV3371
  Oncology Research International Limited3381
  Oncolytics Biotech Inc.3391
  Oncomatryx Biopharma, S.L.3401
  OncoMed Pharmaceuticals, Inc.3411
  Oncovir, Inc.3421
  Ono Pharmaceutical Co., Ltd.3431
  Opsona Therapeutics Limited3441
  Optimum Therapeutics, LLC3451
  Oribase Pharma3461
  Oryx GmbH &Co. KG3471
  Oscotec Inc.3481
  Pfizer Inc.3491
  Pharma Mar, S.A.3501
  Pharma Two B Ltd3511
  PharmAbcine, Inc.3521
  Pharmacyclics, Inc.3531
  PharmaCyte Biotech, Inc.3541
  Pharmedartis GmbH3551
  Phoenix Biotechnology, Inc.3561
  Pique Therapeutics3571
  Plexxikon Inc.3581
  Polaris Pharmaceuticals, Inc.3591
  Precision Biologics, Inc.3601
  Prima BioMed Ltd.3611
  Provectus Biopharmaceuticals, Inc.3621
  Quest PharmaTech Inc.3631
  Quimatryx, S.L.3641
  Raptor Pharmaceutical Corp.3651
  RedHill Biopharma Ltd.3661
  Redx Pharma Plc3671
  RESprotect GmbH3681
  Rexahn Pharmaceuticals, Inc.3691
  Rigontec GmbH3701
  Sanofi3711
  Sareum Holdings Plc3721
  Satt Nord SAS3731
  Savoy Pharmaceuticals, Inc.3741
  SignPath Pharma Inc3751

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Pancreatic Cancer - Pipeline Review, H1 2016" Jun 28, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pancreatic-Cancer-Pipeline-Review-H1-2016-2088-16014>
  
APA:
Global Markets Direct - Market Research. (2016). Pancreatic Cancer - Pipeline Review, H1 2016 Jun 28, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Pancreatic-Cancer-Pipeline-Review-H1-2016-2088-16014>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.